PMID- 33149866
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2008-3866 (Print)
IS  - 2008-3874 (Electronic)
IS  - 2008-3866 (Linking)
VI  - 23
IP  - 10
DP  - 2020 Oct
TI  - Effect of doxycycline and meloxicam on cytokines, brain-derived neurotrophic 
      factor, matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-3 and 
      cyclooxygenase-2 in brain.
PG  - 1328-1334
LID - 10.22038/ijbms.2020.45193.10527 [doi]
AB  - OBJECTIVES: Prevention of inflammation in early stages will be useful in 
      maintaining vitality of the organism. The objective of this study was to evaluate 
      the effects of doxycycline (DOX) or meloxicam (MLX) monotherapy and combination 
      therapy on the levels of inflammatory mediators in the brain tissues of rats with 
      Escherichia coli lipopolysaccharide (LPS)-induced brain inflammation. MATERIALS 
      AND METHODS: Seventy-eight rats were divided into the following groups: control 
      (n=6), LPS (0.5 mug/10 mul intracranial) (n=18), LPS (0.5 mug/10 mul 
      intracranial)+DOX (40 mg/kg intraperitoneal) (n=18), LPS (0.5 mug/10 mul 
      intracranial)+MLX (2 mg/kg intraperitoneal) (n=18) and LPS (0.5 mug/10 mul 
      intracranial)+DOX (40 mg/kg intraperitoneal)+MLX (2 mg/kg intraperitoneal) (n=18) 
      groups. Brain tissues were harvested from all rats in the control group and from 
      six rats each in the four experimental groups at 1, 3 and 6 hr under anaesthesia. 
      The levels of tumor necrosis factor alpha (TNFalpha), interleukin 4 (IL-4), IL-6, IL-10, 
      IL-17, brain-derived neurotrophic factor (BDNF), matrix metalloproteinase 3 
      (MMP-3), tissue inhibitor of metalloproteinase 3 (TIMP-3) and cyclooxygenase 2 
      (COX-2) in the brain tissues were measured using ELISA kits with ELISA device. 
      RESULTS: LPS administration increased proinflammatory cytokines (TNF, IL-6, 
      IL-17), and MMP-3 levels and decreased anti-inflammatory cytokines (IL-10, IL-4), 
      and BDNF levels. The lowest TNFalpha levels were detected in the LPS+MLX group 
      (P<0.05). All the drug treatment groups showed decreased IL-17 and COX-2 levels 
      compared to the LPS groups. CONCLUSION: DOX or MLX monotherapy exerts 
      neuroprotective effects against brain inflammation by decreasing proinflammatory 
      cytokine levels and by increasing anti-inflammatory cytokines levels.
FAU - Er, Ayse
AU  - Er A
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk 
      University, Konya, Turkey.
FAU - Coskun, Devran
AU  - Coskun D
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Siirt 
      University, Siirt, Turkey.
FAU - Bahcivan, Emre
AU  - Bahcivan E
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Kafkas 
      University, Kars, Turkey.
FAU - Dik, Burak
AU  - Dik B
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk 
      University, Konya, Turkey.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Basic Med Sci
JT  - Iranian journal of basic medical sciences
JID - 101517966
PMC - PMC7585535
OTO - NOTNLM
OT  - Brain
OT  - Doxycycline
OT  - Inflammation
OT  - Meloxicam
OT  - Neuroprotective
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:01
PMCR- 2020/10/01
CRDT- 2020/11/05 06:07
PHST- 2020/11/05 06:07 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:01 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - 10.22038/ijbms.2020.45193.10527 [doi]
PST - ppublish
SO  - Iran J Basic Med Sci. 2020 Oct;23(10):1328-1334. doi: 
      10.22038/ijbms.2020.45193.10527.